{
  "docId": "019de071-46a1-7225-9b14-04fe7f7f59d9",
  "docSlug": "2120122995ea0e3bcae2e5ba1ee4dadc",
  "documentTitle": "Mainz Biomed NV | Investor Presentation Deck | 23 slides",
  "authorId": "mainz-biomed-nv",
  "authorName": "Mainz Biomed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 23,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a two-column layout to present six key investment pillars.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-46a1-7225-9b14-04fe7f7f59d9/4",
  "deckHref": "/decks/019de071-46a1-7225-9b14-04fe7f7f59d9",
  "deckJsonHref": "/decks/019de071-46a1-7225-9b14-04fe7f7f59d9.json",
  "deckAnchorHref": "/decks/019de071-46a1-7225-9b14-04fe7f7f59d9#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.03,
        "y": 0.935
      },
      "kind": "disclaimer",
      "text": "Colorectal cancer is the second leading cause of cancer death in the US - Cancer.org",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e25bbbb6-a894-494b-bc3c-ed74dc91e658",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.53,
        "y": 0.3
      },
      "kind": "list",
      "text": "Ease of Use: Non-invasive test, which can be taken at home, with rapid response and 92% accuracy. Cheaper and easier to administer than ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "109db564-d85a-4af8-b222-15d5485b7773",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.12,
        "y": 0.435
      },
      "kind": "list",
      "text": "Revenue Generating: ColoAlert has received CE accreditation and is approved for sale in Europe. European sales provide near-term revenue potential, while we prepare our entry into the US market.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "545463ff-ffb7-47e1-be03-0a72e3880c8e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.12,
        "y": 0.295
      },
      "kind": "list",
      "text": "Significant Impact: Colorectal cancer is the 2nd most lethal cancer in the US, but also the most preventable; with early detection providing survival rates above 90%.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d93f913-f8d3-4704-9ae4-ae9831d4c555",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.12,
        "y": 0.595
      },
      "kind": "list",
      "text": "Blue Sky Potential: We plan on starting the FDA process shortly after our public listing. Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to market potential of over 52 million tests per year.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "997773a6-6fdd-4722-9a3e-e9fee486f545",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.53,
        "y": 0.47
      },
      "kind": "list",
      "text": "Attractive Valuation: Our closest peer, Exact Sciences (NASDAQ: EXAS), which is not approved in the EU, has a market cap of approximately 20 billion USD. Mainz Biomed will IPO at a fraction of this valuation.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0f6e66c-1eaa-4588-80d7-38829d5f9164",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.53,
        "y": 0.62
      },
      "kind": "list",
      "text": "Experienced Management: Seasoned and experienced management with particular skill sets in commercializing and monetizing medical diagnostics at some of the largest medical companies in the world.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d477942f-b8f1-43d7-97c0-049386e8afe5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "Lead product, ColoAlert targets expansion to USA",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7698a1d-cc77-48f3-b38e-566ffdf6ae35",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "INVESTMENT HIGHLIGHTS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc7d2842-726f-4029-9cf8-cd4633383478",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "d85d8b83-db65-4ac1-98a7-8176516f75a7",
      "evidence": "Lead product, ColoAlert targets expansion to USA",
      "confidence": 0.9
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "a42180e6-0ef8-4888-898f-f05298a29b61",
      "evidence": "list/bullet: Blue Sky Potential: We plan on starting the FDA process shortly after our public listing.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}